This article was originally published on Benzinga and appears here with permission.
Numinus Wellness announced the launch of a new clinical trial that will add information to an industry insider debate: isĀ naturally produced psilocybin as good as synthetic psilocybin?
Numinusā new Phase I clinical trial, to be conducted in partnership withĀ , will test out the companyās own naturally derived psilocybin formulation on human subjects.
The trial will enroll 14 healthy volunteers and will assess the safety and psychoactive properties of a Psilocybe mushroom formulation extracted at the Numinus Bioscience lab in British Columbia.
The company holds a license to cultivate and extract magic mushroomsĀ in Canada.
As opposed to most psilocybin clinical trials today, Numinusā study uses a derivative of natural mushroomsĀ instead of a synthesized version of the plant.
The company did not clarify whether the formulation contains isolated psilocybin derived from natural mushrooms, or a full-spectrum formulation, which would include psilocybin and other natural tryptamines.
āWe believe there are several likely advantages to naturally occurring Psilocybin therapeutics that will make them attractive for researchers and consumers alike,ā said Sharan Sidhu, science officer and general manager at Numinus Bioscience.
Ā āWe are confident that this trial will document that natural Psilocybin extractions meet health regulator requirements for safety, efficacy and quality, and ultimately enable the establishment of better access to this medicine,ā she added.
Need a little more Bluntness in your life? Check out our YouTube page!Ā






Complete Guide to Psilocybin Mushroom Strains - The Bluntness Photo by
Complete Guide to Psilocybin Mushroom Strains - The Bluntness Photo by 








